ABSTRACT
The identification and characterization of biomarkers for targeted therapies and more recently immunotherapy in non-small cell lung cancer represent important advances with major therapeutic implications. This section discusses the role of these and other biomarkers in lung cancer diagnosis and management, with particular reference to their role in optimizing treatment according to disease stage.
